Weight-Loss Drugs: New Targets in Health Research

Expansion of Obesity Treatments Beyond Weight Loss

Eli Lilly's diabetes drug Mounjaro and weight-loss therapy Zepbound, along with Novo Nordisk's medications Ozempic and Wegovy, are being explored for their potential to improve health in various other conditions. These drugs have shown promising results in treating not only obesity but also a range of medical issues, indicating a broader application beyond their initial purpose.

Sleep Apnea

One of the most notable findings is that Zepbound helped resolve moderate to severe obstructive sleep apnea in up to 52% of patients in two late-stage trials. This condition, which involves interrupted breathing during sleep, can lead to serious health complications if left untreated. The trials included participants who used respiratory devices as well as those who did not, highlighting the drug's effectiveness across different patient profiles.

Alcohol Addiction

Researchers are investigating whether semaglutide, marketed as Wegovy and Ozempic by Novo Nordisk, can help reduce alcohol intake in patients with alcohol use disorder and obesity. A study conducted by the University of Copenhagen's Psychiatric Centre Rigshospitalet is examining this potential benefit in 108 patients. The results could provide new treatment options for individuals struggling with both addiction and obesity.

Alzheimer’s Disease

Novo Nordisk has initiated a trial to test semaglutide in patients with early Alzheimer’s disease. The study, which will involve 1,840 participants, aims to determine the drug's efficacy in managing the progression of the disease. If successful, this could mark a significant breakthrough in Alzheimer’s treatment, offering hope to millions affected by the condition.

Cardiovascular Disease

Eli Lilly is testing tirzepatide, sold as Mounjaro and Zepbound, for patients with heart failure and obesity. The company plans to enroll about 700 people in the study, which is expected to be completed by July 2024. Additionally, researchers at the Chinese University of Hong Kong are evaluating Novo's semaglutide alongside mechanical clot removal in stroke patients. This mid-stage study aims to recruit around 140 participants and compare the new approach with standard therapy.

Chronic Kidney Disease

Novo's Ozempic has shown promise in delaying the progression of chronic kidney disease in diabetes patients, reducing the risk of death from that condition and major cardiac events by 24%. However, this result fell short of investor expectations. Lilly is also conducting a mid-stage study on tirzepatide for chronic kidney disease in obese patients, planning to enroll up to 140 participants.

Liver Disease

Novo is testing semaglutide in a late-stage trial for non-alcoholic steatohepatitis (NASH), a common type of fatty liver disease. The study is expected to enroll about 1,200 patients. Meanwhile, Lilly's tirzepatide showed impressive results in a mid-stage trial for metabolic dysfunction-associated steatohepatitis (MASH), with up to 74% of patients achieving absence of the disease without worsening liver scarring, compared to 13% on placebo.

Neurological Disorders

Researchers at the Danish Headache Center are exploring semaglutide combined with a very low-calorie diet as a treatment for new-onset idiopathic intracranial hypertension, a condition linked to obesity. The study aims to recruit around 50 patients and is expected to conclude as early as 2025.

These ongoing studies highlight the potential of obesity treatments to address a wide array of health conditions, offering new possibilities for patients and healthcare providers alike. As research continues, the impact of these drugs on various medical fields may become even more significant.